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background:  It is little known as long-term clinical outcomes for coronary artery spasm.
methods: A total 1118 patients (pts) undergoing coronary angiography with acetylcholine provocation test from Nov 2004 to Oct 2010 from 
prospective spasm registry of Cardiovascular Center of Korea University Guro Hospital were enrolled. The follow-up duration was 5-year. The definition 
of positive coronary spasm test was defined as coronary vasospasm of more than 70%. After propensity score matching, the patient number of both 
group was 421.
results: After Propensity score matching, there was no difference in mortality, cardiac death, myocardial infarction except recurrent chest pain 
requiring repeat coronary angiography that had the higher incidence in positive CAS group (p=0.003) (Table). Also, in proportional hazard cox-
regression analysis adjusted by co-variates such as age, gender, hypertension, diabetes, dyslipidemia, current smokers, current alcoholics, myocardial 
bridge, positive CAS was associated with the increase of incidence of recurrent chest pain (HR, 1.7; 95% CI, 1.012-2.612; p=0.022).
Conclusions: In our study, coronary artery spasm didn’t increase the incidence of mortality, cardiac death, and myocardial death except recurrent 
chest pain during 5-year clinical follow-up period.
 
